UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 2, 2022

Context Therapeutics Inc. (Exact name of registrant as specified in its charter)

D-1	001-40654	00.0700707
Delaware	001-40054	86-3738787
(State of other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

2001 Market Street, Suite 3915, Unit#15 Philadelphia, Pennsylvania 19103 (Address of principal executive offices including zip code)

(267) 225-7416

(Registrant's telephone number, including area code)

Not Applicable (Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the

Written communications pursuant to Rule 425 under t	he Securities Act (17 CFR 230.425)				
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)					
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))					
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))					
	Trading	Name of exchange			
Title of each class	Symbol	on which registered			
Common Stock	CNTX	The Nasdaq Stock Market			
\$0.001 par value per share					

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ⊠

following provisions:

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. \square

Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 2, 2022, Context Therapeutics Inc. ("the Company") held its Annual Meeting of Stockholders. As of April 4, 2022, the record date for the Annual Meeting, there were 15,966,053 shares of Company common stock issued and outstanding and entitled to vote on the proposal presented at the Annual Meeting, of which 9,161,941, or approximately 57.38%, were present or represented by proxy, which constituted a quorum. The holders of shares of Company common stock are entitled to one vote for each share held. Set forth below are the final voting results for the proposal submitted to a vote of the Company's stockholders at the Annual Meeting, which was described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on April 4, 2022.

Proposal 1. Ratification of Selection of Independent Registered Public Accounting Firm

The Company's stockholders ratified the appointment of CohnReznick LLP as the Company's independent registered public accounting firm for the year ending December 31, 2022. The voting on this proposal is set forth below:

	<u>For</u>	<u>Against</u>	<u>Abstentions</u>	Broker Non-Votes
Ratification of CohnReznick				
LLP	9,144,524	8,877	8,540	

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: June 3, 2022

Context Therapeutics Inc.

By: <u>/s/ Martin Lehr</u> Name: Martin Lehr

Title: Chief Executive Officer